Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
20 September 2019

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Sun Pharmaceuticals Industries Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 411.15
Net Changes 0.00
Volume 4238714
Prev Close 411.15
411.15 0.00 (0.00%)
Date: Sep 19,2019 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 0 Div Yield (%) 0.67
Buy (Size) 415.00(×50) Eps(Rs) 9.13
Sell (Size) 411.00(×21) Book Value(Rs) 95.2081047
Buy Quantity 50 Market Cap(Rs.Cr) 98588.67
Sell Quantity 21 Face Value(Rs) 1
Today's High 0 Market Lot 1
Today's Low 0 AGM Date Aug
52-Week High 657 Book Closure Date Aug
52-Week Low 0 ISIN No. INE044A01036

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 1304855381 54.38
Total of Promoter 1304855381 54.38
Non Promoter (Institution) 789571100 32.91
Non Promoter (Non-Institution) 304908489 12.71
Total Non Promoter 1094479589 45.62
Total Promoter & Non Promoter 2399334970 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 2399334970 100.00

Company News

17-Sep-2019  Sun Pharmaceuticals Industries Ltd - Compliances-Reg. 39 (3) -...
Sun Pharmaceuticals Industries Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Please find enclosed intimation under regulation 39(3)
16-Sep-2019  Sun Pharmaceuticals Industries Ltd - Compliances-Reg. 39 (3) -...
Sun Pharmaceuticals Industries Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Please find enclosed intimation under regulation 39(3)
12-Sep-2019  Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31...
Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd
11-Sep-2019  Sun Pharma gains as unit acquires remaining stake in PJSC Bios...
Sun Pharma gains as unit acquires remaining stake in PJSC Biosintez

On the BSE, 761 shares were traded in the counter so far compared with average daily volumes of 6.21 lakh shares in the past two weeks. The stock hit a high of Rs 432.30 and a low of Rs 430.10 so far during the day.

Sun Pharmaceutical Industries said that the wholly owned subsidiary of the company - Sun Pharma (Netherlands) BV has increased its shareholding in PJSC Biosintez, Russia, by way of purchase of 8698 shares (2391 ordinary shares and 6307 preferred shares) equivalent to 3.04% of PJSC Biosintez under Mandatory Tender Offer. The announcement was made after market hours on Monday, 9 September 2019.

Post completion of this purchase of shares, the total holding of wholly owned subsidiary company was increased from 96.96% to 100% in PJSC Biosintez. The total cost of acquisition is $815,201.99.

PJSC Biosintez is mainly engaged in the manufacture and marketing of pharmaceutical products used in hospital segment of the market. The company has presence in Russia and CIS countries.

On a consolidated basis, the pharmaceutical company's net profit rose 31.2% to Rs 1,387.48 crore on a 15.7% rise in the net sales to Rs 8,259.30 crore in Q1 June 2019 over Q1 June 2018.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

11-Sep-2019  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Updates

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
09-Sep-2019  Sun Pharmaceuticals Industries acquires balance stake in PJSC...
Sun Pharmaceuticals Industries acquires balance stake in PJSC Biosintez, Russia

Sun Pharmaceuticals Industries announced that the wholly owned subsidiary of the company has increased its shareholding in PJSC Biosintez, Russia, by way of purchase of 8698 shares (2391 ordinary shares and 6307 preferred shares) equivalent to 3.04% ofPJSC Biosintez under Mandatory Tender Offer.

Post completion of this purchase of shares, the total holding of wholly owned subsidiary company was increased from 96.96% to 100% in PJSC Biosintez.

09-Sep-2019  Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31...
Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditya Medisales Ltd
09-Sep-2019  Sun Pharmaceuticals Industries Ltd - Announcement under Regula...
Sun Pharmaceuticals Industries Ltd - Announcement under Regulation 30 (LODR)-Updates on Acquisition

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
05-Sep-2019  Sun Pharmaceuticals Industries Ltd - Clarification / Confirmat...
Sun Pharmaceuticals Industries Ltd - Clarification / Confirmation On News Item

Clarification / Confirmation on news item
04-Sep-2019  Sun Pharma slides on reports of forensic audit
Sun Pharma slides on reports of forensic audit

Meanwhile, the S&P BSE Sensex was up 10 points or 0.03% to 36573.36.

The Sun Pharmaceutical Industries scrip is currently trading lower by 7.22% at Rs 407.70. The stock hit a high of Rs 426.95 and a low of Rs 406 so far during the day. On the BSE, 6.68 lakh shares were traded in the counter so far compared with average daily volumes of 4.20 lakh shares in the past two weeks.

As per reports, Securities and Exchange Board of India (Sebi) has ordered a forensic audit against Sun Pharmaceutical Industries to look into allegations of financial irregularities and lapses in corporate governance standards. The audit has been reportedly ordered based on allegations made by a whistleblower in a 150-page complaint to Sebi, accusing Sun Pharma of committing corporate governance and tax-related offences and securities market-related violations.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Incorporation Year 1993 
Registered Office Sun Pharma Advanced Res.Centre,Tandalja,
,
Gujarat-390020
Telephone 91-265-6615500 
Fax 91-265-2354897 
Chairman Israel Makov
Managing Director Dilip S Shanghvi
Company Secretary Sunil R Ajmera 
Auditor S R B C & Co LLP 
Face Value(Rs)
Market Lot
Listing MSEI,BSE,NSE 
Registrar Link Intime India Pvt Ltd
C-101 247 Park,L B S Marg,Vikhroli West,Mumbai-400083 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS